10:53 AM EST - ProMIS Neurosciences Inc. : A biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease, amyotrophic lateral sclerosis and multiple system atrophy, presented preclinical data further supporting the potential therapeutic advantage of lead candidate for AD, PMN310, a humanized IgG1 antibody directed toward toxic amyloid-beta oligomers. ProMIS Neurosciences Inc.
shares T.PMN are trading up $3.76 at $7.40.
